Results 91 to 100 of about 1,134 (185)

Treatment of MRL/lpr mice with astilbin ameliorates disease development associated with lupus.

open access: yes, 2015
A. Representative lymph nodes and spleen from MRL/lpr mice treated with astilbin or CTX starting at 8 weeks of age (left panel). The lymph nodes and spleen from treated mice were weighed and graphed as mean ± SEM (right panel). B.
Wen Liu (39804)   +10 more
core   +1 more source

Astilbin attenuated pyroptosis caused by terbuthylazine-induced histone lactylation in grass carp hepatocytes

open access: yesEcotoxicology and Environmental Safety
Terbuthylazine (TER), a triazine herbicide, can trigger excessive production of reactive oxygen species (ROS) in organisms, leading to liver damage in aquatic species.
Yu Xia   +8 more
doaj   +1 more source

Difference Analysis of Non-Volatile and Volatile Components in Kujingcha (Ilex dabieshanensis) Compared with Green Tea (Camellia sinensis)

open access: yesHorticulturae
Kujingcha (KJC) is a widely consumed substitute tea due to its unique flavor quality and health benefits. However, the biochemical basis for the formation of KJC’s unique flavor quality and health benefits remain unclear.
Linlong Ma   +10 more
doaj   +1 more source

Astilbin treatment decreases the percentage of CD19-B220-CD138+ plasma cells and BAFF mRNA expression.

open access: yes, 2015
MRL/lpr mice were treated with astilbin (10, 20, 40 mg/kg) starting at 8 weeks or astilbin (20 mg/kg) at 12 weeks of age. Flow cytometry analysis of whole splenocytes stained with CD19-FITC, CD138-PE, B220–APC was performed at 20 wk. A.
Wen Liu (39804)   +10 more
core   +1 more source

Exploring the Therapeutic Potential of Natural Compounds in Psoriasis and Their Inclusion in Nanotechnological Systems

open access: yesAntioxidants
Psoriasis is a chronic inflammatory disease that affects around 2–3% of the world’s population. The treatment for this autoimmune disease still remains centered around conventional methods using synthetic substances, even though more recent advancements ...
Ana Flavia Burlec   +4 more
doaj   +1 more source

Astilbin treatment decreases the percentage of CD44hiCD62Llo activated CD4+ T cells and several cytokine mRNA expression.

open access: yes, 2015
MRL/lpr mice were treated with astilbin (10, 20, 40 mg/kg) starting at 8 weeks or astilbin (20 mg/kg) at 12 weeks of age. Flow cytometry analysis of whole splenocytes stained with CD3e-percp-cy5.5, CD44-FITC, CD62L-PE, CD4–APC was performed at 20 wk.
Wen Liu (39804)   +10 more
core   +1 more source

Astilbin Alleviates Gouty Arthritis via Regulating NLRP3 Inflammasome and NF-κB Signaling Pathway: A Comprehensive Study on In Vitro and In Vivo Experimental Models

open access: yes
Background/Objectives: Gouty arthritis (GA) is an inflammatory disease caused by increased purine metabolism. The limitations of current anti-GA therapies remain a major challenge.
Yan Huang   +5 more
core   +1 more source

GelMA@LNP/AST Promotes eNOS-Dependent Angiogenesis Through Autophagy Activation for the Treatment of Hind Limb Ischemia

open access: yesInternational Journal of Nanomedicine
Lingzhi Lai,1 Hao Wu,1 Liang Peng,2 Zhen Zhang,3 Xinfan Wu,1 Shuo Zheng,3 Zekang Su,3 Hongxing Chu3 1Maoming People’s Hospital, Maoming, Guangdong, People’s Republic of China; 2The First People’s Hospital of Guiyang, Guiyang, Guizhou, People’s Republic ...
Lai L   +7 more
doaj  

Astilbin from </em>Smilax glabra</em> Roxb. as a pro-apoptotic agent: cytotoxicity in multiple cancer cell lines and selectivity for 5637 bladder carcinoma

open access: yes
This study aims to evaluate the cytotoxic and pro-apoptotic effects of astilbin, derived from Smilax glabra Roxb., on multiple cancer cell lines, including 5637 (human bladder carcinoma), A549 (lung carcinoma), and HeLa (cervical adenocarcinoma), with a ...
Phuong Nguyen Thi Mai Phuong   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy